[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nicotine-addiction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nicotine-addiction":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,43,75,99,123,147,175,201,231,261],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100615922","non-invasive-deep-brain-neuromodulation-for-smoking-cessation-100615922",false,"NCT07298902","Non-Invasive Deep Brain Neuromodulation for Smoking Cessation","Inclusion Criteria:\n\n1. Must be a smoker for 5 or more years and within 20 to 60 years of age\n2. Must not meet exclusion criteria for MRI scanning (e.g., non-fixed magnetizable objects)\n3. Must not have ongoing unstable medical, neurological or psychiatric illness as determined by a combination of history, medical record, and\u002For examination.\n4. Must be a current smoker with average of 5 cigarettes or more a day for the last month or longer.\n5. Report 3 or more trials of smoking cessation attempts using nicotine replacement, e-cig, TMS, varenicline or other smoking cessation drugs, psychotherapy or other means.\n\nExclusion Criteria:\n\n1. Failed TMS screening questionnaire.\n2. Significant alcohol or other drug use (substance dependence within the recent months) or positive urine toxicology screen for substance not prescribed other than nicotine or marijuana dependence.\n3. Cannot refrain from using alcohol and\u002For marijuana 24 hours or more prior to experiments.\n4. Taking \\> 400 mg clozapine\u002Fday and not on anti-seizure medication(s) with sufficient dose.\n5. Woman who is pregnant (child-bearing potential but not on contraceptive and missing menstrual period; or by self-report; or by positive pregnancy test) or has had unprotected sexual intercourse without birth control in the last 4 weeks.\n6. In ongoing smoking cessation treatment, clinical trial, or nicotine replacements (except for the current study)",true,"ALL","20 Years","60 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study will develop novel low intensity focused ultrasound (LIFU) therapy to help people to quit cigarette smoking. Smoking is associated with cancers of the lung. Available smoking cessation methods help many to quit. However, for the many who continue to smoke despite the strong desire to quit and after exhausting existing therapeutic approaches, new treatment methods are needed. Without more effective treatment, many will continue to smoke, and our progress on cancer prevention through smoking cessation may decelerate as these associated cancer risks will remain. Brain imaging research has identified specific areas of the brain linked to severe nicotine addiction, but up to now there are no effective ways to directly target most of these deeper brain regions. LIFU is a new and safe method to modulate brain functions that can either inhibit overactive activity or restore normal activity levels. The purpose of this study is to provide a novel ultrasound-based neuromodulation strategy for smoking cessation in people who have difficulty to quit smoking despite numerous serious attempts in their lives. LIFU works by sending acoustic pressure modulating neural activity in the human brain.",[27],"Nicotine Addiction",[29],"low intensity focused ultrasound","RECRUITING","2026-06-18",{"date":33,"type":34},"2026-06-23","ACTUAL",{"date":36,"type":34},"2026-04-13",{"date":38,"type":21},"2030-11-30",{"name":40,"class":41},"The University of Texas Health Science Center, Houston","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":15,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100577854","metabolome-and-gut-microbiome-changes-during-smoking-cessation-in-long-term-drug-therapy-in-a-therapeutic-community-100577854","NCT06803706","Metabolome and Gut Microbiome Changes During Smoking Cessation in Long-term Drug Therapy in a Therapeutic Community","Metabolomic and Gut Microbial Biomarkers of Smoking Cessation Treatment in Long-term Drug Therapy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* diagnosis of a form of substance use disorder (F1x.x) by a licensed psychiatrist according to ICD-10\n* minimum age of 18 years\n* sufficient knowledge of the German language\n* willingness to quit smoking\n* willingness and ability to consent\n\nInclusion criteria for healthy controls :\n\n* minimum age of 18 years\n* sufficient knowledge of the German language\n* willingness and ability to consent\n\nExclusion Criteria:\n\n* lack of consent, inability to provide informed consent\n* age below 18,\n* acute psychotic symptoms or acute suicidal tendencies\n* cardiovascular disease\n* pregnancy or breastfeeding\n* severe mental or organic illnesses (such as epilepsy, brain tumors, recent major surgery), tumor diseases, dementia (Mini Mental Score \\\u003C20), severe autoimmune diseases or immunosuppression, acute infections, or acute diarrhea, prior gastrointestinal surgery (except appendectomy)\n* probiotic intake within the last 6 months,\n* ongoing consumtion of dietary supplements, probiotics, antibiotics, or prebiotic supplements during the study\n* prior participation in a smoking cessation programme","18 Years",{"count":52,"type":21},150,[24],"Theoretical Framework: Cigarette smoking is the leading preventable cause of death worldwide, with nicotine dependence notably common among individuals with Substance Use Disorders (SUD). Smoking exacerbates both physical and mental health issues, further complicating the treatment of SUD. Current therapeutic approaches for SUD often prove inadequate, indicating a need for new strategies. Recent advancements in metabolomics and gut microbiome research have provided valuable insights into the biological mechanisms underlying addiction.\n\nObjectives: This study aims to investigate the therapeutic potential of smoking cessation for individuals with SUD, using a six-week intervention within a therapeutic community. The research specifically explores the psychobehavioral, metabolic, and gut microbiome domains. It is hypothesized that smoking cessation will improve emotional regulation, self-efficacy, and reduce substance craving, mediated by changes in metabolic and microbiome profiles linked to brain reward systems.\n\nMethods: A randomized controlled trial (N=150) will be conducted, examining outcomes such as clinical relapse rates, microbial and metabolic markers, particularly in choline and folate metabolism. Participants with SUD (n=100) will undergo a six-week smoking cessation intervention, with pre- and post-assessments, compared to a control group receiving treatment as usual. Metabolomic and microbiome analyses will be conducted using blood and stool samples, alongside psychological assessments via questionnaires. Assessments on a behavioural level will take place at a 3-months follow-up.\n\nA cross-sectional, non-interventional healthy control group (n=50) will be examined at a single timepoint with an anologous panel of psychological variables, blood and stool to ascertain differences between smokers with SUD and healthy controls.",[56,57,27,58],"Substance Use Disorder (SUD)","Alcohol Use Disorder (AUD)","Healthy Adult Participants",[60,61,62,63,64],"Metabolomics","Gut microbiome","Substance use disorder","nicotine addiction","smoking cessation","2026-05-15",{"date":67,"type":34},"2026-05-18",{"date":69,"type":34},"2025-05-05",{"date":71,"type":21},"2026-10-28",{"name":73,"class":41},"Sigmund Freud PrivatUniversitat",3,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":42},"100597506","phase-3-semaglutide-for-smoking-cessation-in-patients-with-diabetes-100597506","NCT07059377","Semaglutide for Smoking Cessation in Patients With Diabetes","Semaglutide for Smoking Cessation in Patients With Diabetes: A Pilot Randomized Controlled Trial","GLP1-SC","Inclusion Criteria:\n\n* Adults (18 years or older) with type 2 diabetes\n* Currently residing in Ontario\n* Smoke at least five cigarettes per day and willing to reduce or quit smoking within the next 6 months\n* Stable HbA1c ≥7.0% - 10% with no more than a 1% change over the last 3 to 6 months.\n* Have not used GLP-1 receptor agonists in the past six months.\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding individuals\n* Contraindication to NRT or GLP-1 RA.\n* Current daily use of NRT or a GLP1 RA.\n* Use of bupropion, cytisine, and varenicline within the last 7 days.\n* Use of a DPP-IV inhibitor within the last 7 days.\n* Initiation of a new diabetes medication within the last 3 months.\n* As per the product monograph, participants with the following diagnoses or disorders will be excluded;\n* Personal or family history of medullary thyroid cancer\n* Personal or family history of Multiple Endocrine Neoplasia syndrome type 2\n* Diabetic ketoacidosis\n* Type I diabetes\n* Acute pancreatitis or pancreatic cancer\n* Acute, chronic or end-stage renal failure\n* Tachyarrhythmias\n* Unable to engage in follow-up for any reason (for example an acute mental illness, cognitive impairment, unable to speak English or French).\n* Other conditions deemed by the study team to interfere with participation or outcomes in the opinion of the study investigator (for example acutely unwell, life expectancy less than 1 year).",{"count":20,"type":21},[85],"PHASE3","To assess the feasibility of conducting a randomized controlled trial (RCT) to determine the effectiveness of semaglutide as an adjunct to combination NRT in supporting smoking cessation for patients with diabetes.",[88,27,89],"Diabetes Mellitus, Type 2","Tobacco Dependence","2026-05-05",{"date":92,"type":34},"2026-05-11",{"date":94,"type":34},"2026-02-13",{"date":96,"type":21},"2027-07",{"name":98,"class":41},"Ottawa Heart Institute Research Corporation",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":106,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":42},"100560879","early-phase-1-advancing-vr-based-attentional-bias-as-a-biomarker-for-tobacco-use-disorder-100560879","NCT06582888","Advancing VR-based Attentional Bias as a Biomarker for Tobacco Use Disorder","VR","Inclusion Criteria:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Persons, aged 22+\n4. Ability to take oral medication and be willing to adhere to the dosing regimen\n5. For participants able to become pregnant: use of highly effective contraception during study enrollment\n6. Current daily tobacco use (use on 7 days per week, on average, ≥5 cigarettes per day, in the previous 3 months)\n7. Tobacco use history ≥3 years\n8. Endorsement of past week nicotine craving\n\nExclusion Criteria:\n\n1. Contraindications\u002Fconditions with special precautions for varenicline treatment (i.e., history of serious hypersensitivity or skin reactions to varenicline, history of severe renal impairment, seizures, severe cardiovascular disease, chronic or severe nausea, Stevens-Johnson syndrome, erythema multiforme, pregnancy or nursing)\n2. Medical or psychiatric history affecting brain development (i.e., history and\u002For treatment of neurologic disorders, severe head trauma with loss of consciousness \\>2 minutes, or current severe Diagnostic and Statistical Manual 5th edition (DSM-5) psychiatric disorders other than tobacco use disorders)\n3. Current suicidal ideation or history of suicide attempt or self-mutilatory acts in the past 12 months\n4. Other recreational drug use in the past 30 days (besides alcohol and cannabis) verified by oral and urine fluid toxicology\n5. Visual\u002Fvestibular problems that may make task completion difficult (i.e., motion sickness, difficulty balancing, blindness)\n6. Treatment seeking for tobacco use disorder\u002Fintent to quit within 30 days","22 Years",{"count":108,"type":21},200,[110],"EARLY_PHASE1","The proposed project will include enrollment of 200 daily tobacco cigarette users, ages 22+, from the San Diego community. Participants will be assessed on the VR Nicotine Cue Exposure paradigm then randomized (stratified on age and sex) to receive varenicline (target dose 1mg twice daily) or placebo (n per group=100; total N=200). Following eight days of titration, participants will be assessed again on the VR Nicotine Cue Exposure paradigm. They will then be followed via mobile assessments for eight days on target dose of varenicline, and 30-days post assessment by phone, to assess short-term nicotine use behaviors.",[27,113],"Craving","2026-03-12",{"date":116,"type":34},"2026-03-16",{"date":118,"type":34},"2024-11-19",{"date":120,"type":21},"2028-08-15",{"name":122,"class":41},"University of California, San Diego",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":15,"sex":16,"minAge":129,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":22,"phases":133,"briefSummary":134,"conditions":135,"keywords":136,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":143,"leadSponsor":145,"locationsCount":42},"100605691","effect-of-product-characteristics-on-the-abuse-liability-of-nicotine-pouches-100605691","NCT07165808","Effect of Product Characteristics on the Abuse Liability of Nicotine Pouches","Inclusion Criteria:\n\n* Current established users of nicotine pouches (have used nicotine pouches in the past 30 days \\& currently use nicotine pouches every day or someday)\n* Positive cotinine test via saliva test strip\n* Those who are unmotivated to quit nicotine use\n* Read and speak English.\n* Poly-users of nicotine pouches, e-cigarettes (e.g., vape ≥20 days\u002Fmonth), and tobacco (e.g., ≥4 cigarettes\u002Fday for ≥2 years) will be eligible for participation\n\nExclusion Criteria\n\n* Planning to cut down or quit using nicotine in the next 30 days\n* Currently pregnant or breastfeeding\n* History of stroke, seizures, high blood pressure, heart disease\u002Fproblems, or cardiovascular disease contraindications for nicotine.","21 Years","35 Years",{"count":132,"type":21},84,[24],"The goal of this study is to assess the effects of nicotine concentration and its interplay with pH on sensory experience, product appeal, and abuse liability of NPs among young adults NP users.\n\nPrimary objective is to assess the effect of variation in nicotine concentration in nicotine pouches (NPs) and its interaction effect with pH level on three proximal outcomes of relevance to regulation: (1) sensory experience, (2) product appeal, and (3) abuse liability of NPs.",[27],[27,137,138],"Oral Nicotine Pouches","Behavioral Responses","2026-02-25",{"date":141,"type":34},"2026-02-27",{"date":94,"type":34},{"date":144,"type":21},"2028-01",{"name":146,"class":41},"Emory University",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":16,"minAge":106,"maxAge":153,"enrollmentInfo":154,"targetDuration":4,"studyType":22,"phases":156,"briefSummary":157,"conditions":158,"keywords":161,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":42},"100460471","circuitry-guided-smoking-cessation-in-schizophrenia-uh3-100460471","NCT05276050","Circuitry-Guided Smoking Cessation in Schizophrenia (UH3)","Inclusion Criteria:\n\n1. Male and female between ages 22-65 years\n2. Ability to give written informed consent\n3. Smoking in the last one year or more and average cigarette per day ≥ 5 in the past 4 weeks\n4. Diagnosed with schizophrenia-spectrum disorder and Evaluation to Sign Consent (ESC) above10.\n5. Is currently under the care of a licensed primary care provider or mental healthcare provider (e.g., psychiatrist, psychologist, nurse practitioner, licensed clinical social worker).\n6. Agrees to: (a) provide written permission, as requested, to allow any and all forms of communication between the investigators and study staff and any health care provider who currently provides and\u002For has provided service to the subject within two years of study enrollment; and (b) provide the names and verifiable contact information (name, email and mailing address, mobile and land-line phone number, as applicable) of at least two reliable persons ≥ age 22, who reside within a 30-minute drive of the subject's residence, and whom the research staff is at liberty to contact, as deemed necessary, for the duration of study participation.\n\nExclusion Criteria:\n\n1. Persons with a first-degree relative with inherited epilepsy, seizure disorder, or seizures or persons who answer \"yes\" to any of the parts (A. - G.) of Question 3 of an epilepsy screening questionnaire.\n2. Had smoking cessation treatment, clinical trial, or nicotine replacements within the past four weeks.\n3. Significant alcohol or other drug use (substance dependence within 6 months or substance abuse within 1 month) other than nicotine or marijuana dependence.\n4. Any major medical illnesses that may affect normal brain functioning. Examples of these conditions include, but not limited to, stroke, CNS infection or tumor, other significant brain neurological conditions.\n5. Taking \\> 400 mg clozapine\u002Fday or Failed TMS screening questionnaire.\n6. Cardiac pacemakers, implanted medication pumps, intracardiac lines, or acute, unstable cardiac disease, with intracranial implants (e.g. aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed.\n7. History of head injury with loss of consciousness over 10 minutes; history of brain surgery\n8. Cannot refrain from using alcohol and\u002For marijuana 24 hours or more \\& cigarette smoking one hour or more prior to experiments.\n9. Woman who is pregnant (child-bearing potential but not on contraceptive and missing menstrual period; or by self-report; or by positive pregnancy test) or has had unprotected sexual intercourse without birth control in the last 4 weeks.\n10. Moderate-High Risk of suicide according to the Columbia - Suicide Severity Rating Scale (C- SSRS) Screen Version - Recent (i.e. answers YES to Question 3 and NO to Question 6 (Moderate risk); or answers YES to Questions 4, 5, or 6 (High risk) or in the clinical judgement of the investigator or the study psychiatrist.\n11. In the medical opinion of the investigator, subjects with the following circumstances or conditions which can increase the risk of seizures may be excluded: sleep deprivation; major depressive disorder comorbid with dementia, underweight status; concurrent use of cephalosporins and antiarrhythmics (particularly propranolol); metabolic abnormalities (hyponatremia, hypocalcemia, hypomagnesemia, hypoglycemia, hyperglycemia, renal failure\u002Furemia, liver failure); raised blood concentrations of proconvulsant medications due to reduced clearance (e.g. secondary to initiation of antibiotics for treatment of infections); alcohol withdrawal; use of stimulants, such as cocaine or MDMA; use of immunosuppressive therapy with cyclosporine, tacrolimus and other agents that can cause the posterior reversible leukoencephalopathy syndrome; dialysis; systemic infection, and fever itself.","65 Years",{"count":155,"type":21},50,[24],"Patients with schizophrenia spectrum disorder (SSD) will be exposed to active repetitive transcranial magnetic stimulation (rTMS) from F8 coil or active rTMS from H coil for smoking cessation. Smoking and brain functional connectivity changes will be assessed at baseline, different stages of rTMS and\u002For follow-ups.",[159,27,160],"Smoking Cessation","Schizophrenia",[162,163,164,165,166],"Transcranial magnetic stimulation","schizophrenia","smoking","nicotine","tobacco","2026-01-08",{"date":169,"type":34},"2026-01-12",{"date":171,"type":34},"2022-06-01",{"date":173,"type":21},"2027-01-30",{"name":40,"class":41},{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":15,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":22,"phases":184,"briefSummary":185,"conditions":186,"keywords":190,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":42},"100594502","connect-cancer-survivors-with-tobacco-treatment-100594502","NCT07020273","CONNECT Cancer Survivors With Tobacco Treatment","Cancer Prevention by Reducing Tobacco With Informatics and Chronic Care Approaches Trial (CONNECT)","Eligibility Criteria:\n\n* Be receiving care at a participating clinic\n* Report current tobacco use (assessed by the rooming staff during the index visit)\n* Have a completed appointment with a participating clinic\n* Be an adult (at least 18 years old).",{"count":183,"type":21},5000,[24],"The purpose of this study is to evaluate the comparative effectiveness of two different informatics-enabled implementation strategies on increasing tobacco treatment and improving smoking cessation rates for cancer control and prevention. This will be done via a two-arm pragmatic cluster randomized trial (CRT) to test the effectiveness of nudges to change (ELEVATE-S) vs. quit-focused usual care (ELEVATE) in increasing tobacco treatment (use of medication, brief advice, or referral to external counseling) and smoking cessation.",[187,188,159,27,189],"Tobacco Use","Tobacco Use Cessation","Tobacco Smoking",[191,192],"Patient Reported Outcomes","Tobacco Treatment","2026-01-06",{"date":167,"type":34},{"date":196,"type":34},"2025-07-01",{"date":198,"type":21},"2027-01-01",{"name":200,"class":41},"Washington University School of Medicine",{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":207,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":18,"enrollmentInfo":209,"targetDuration":4,"studyType":210,"phases":4,"briefSummary":211,"conditions":212,"keywords":217,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":42},"100552307","unraveling-the-genetic-basis-of-nicotine-addiction-for-novel-therapeutic-strategies-100552307","NCT06471387","Unraveling the Genetic Basis of Nicotine Addiction for Novel Therapeutic Strategies","Exploring the Genetic and Molecular Underpinning of Nicotine Addiction for the Development of New Therapeutic Strategies","NicoGen","Inclusion Criteria:\n\n* Adults aged 18-60 years old\n* Current daily cigarette smoker\n* Able to understand study procedures and provide informed consent\n* For females, non-pregnant and non-lactating\n\nExclusion Criteria:\n\n* Presence of significant uncontrolled medical conditions (e.g. cardiovascular disease, respiratory disorders, cancer) that could affect smoking behaviors or study participation\n* Presence of major uncontrolled psychiatric disorders (e.g. schizophrenia, bipolar disorder, severe depression)\n* Current substance use disorder (except nicotine dependence)\n* Taking medications that could significantly interfere with study objectives (e.g. medications for smoking cessation)\n* Significant cognitive impairment that precludes ability to complete study procedures",{"count":108,"type":21},"OBSERVATIONAL","This case-control study aims to investigate the genetic and molecular bases of nicotine addiction to identify potential therapeutic targets. The project will involve drug repurposing using Mendelian Randomization, a smoking cessation intervention, and the analysis of methylation status in participants undergoing nicotine withdrawal.",[159,213,27,214,215,216],"Smoking Cessation Intervention","Epigenetics","Molecular Biology","Genetic Epidemiology",[27,159,218,219,216,220,221],"Mendelian Randomization","Methylation","Drug Repurposing","Epigenetic Biomarkers","2024-06-23",{"date":224,"type":34},"2024-06-25",{"date":226,"type":34},"2023-11-01",{"date":228,"type":21},"2025-10-31",{"name":230,"class":41},"University of Cyprus",{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":18,"enrollmentInfo":239,"targetDuration":4,"studyType":22,"phases":240,"briefSummary":241,"conditions":242,"keywords":245,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":42},"100552225","biopsychosocial-predictors-of-nicotine-relapse-100552225","NCT06470321","Biopsychosocial Predictors of Nicotine Relapse","Identifying Biomarkers of Stress-induced Neurophysiological Changes and Emotion Regulation Deficits to Predict Relapse During Nicotine Abstinence","BioNic","Inclusion Criteria:\n\n* Age 18-60 years\n* Smoking at least 10 cigarettes daily for at least 2 years\n* Intention to quit smoking\n* Medication-free\n\nExclusion Criteria:\n\n* Presence of psychiatric or medical treatment\n* Pregnancy\n* Current unstable medical illness\n* Recent (prior 6 months) drug or alcohol use disorder\n* Major Depression\n* Diagnosis of psychotic disorder",{"count":108,"type":21},[24],"This study aims to investigate the associations between emotion regulation ability, stress-induced neural activity changes, and susceptibility to relapse in smokers attempting to quit. Participants will undergo assessments of emotion regulation, neural activity via quantitative electroencephalography (qEEG), and stress responses before and during a 24-hour nicotine abstinence period. They will then participate in a computerized smoking cessation intervention, and their abstinence status will be monitored for 6 months.",[243,159,27,244],"Smoking","Tobacco Smoking Behavior",[246,247,248,249,250,251,252],"Nicotine","Relapse","Vulnerability","Biomarkers","EEG","HRV","Stress Reactivity","2024-06-17",{"date":255,"type":34},"2024-06-24",{"date":257,"type":34},"2022-01-01",{"date":259,"type":21},"2025-05-01",{"name":230,"class":41},{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":22,"phases":270,"briefSummary":272,"conditions":273,"keywords":277,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":42},"100535605","phase-4-effectiveness-of-combined-tobacco-treatment-in-hospitalized-subjects-100535605","NCT06254001","Effectiveness of Combined Tobacco Treatment in Hospitalized Subjects","Effectiveness of Combined Treatment of Bupropion and Nicotine Replacement Therapy in Hospitalized Subjects With Active Smoking in a Reference Center","Inclusion Criteria:\n\n\\>18 years Active smokers (consumption of more than 100 cigarettes in their entire life, and who have consumed cigarettes in the last 30 days) Hospitalized subjects Informed consent\n\nExclusion Criteria:\n\n* Subjects who have had pharmacological treatment to stop smoking in the last month\n* Subjects with contraindications for medications.\n\nSample size calculation, 80% power, unilateral, due to difference in proportions, estimated loss of 25%.",{"count":269,"type":21},134,[271],"PHASE4","In the 20th century, tobacco caused the death of 100 million people worldwide and it is estimated that it will be responsible for 1 billion deaths in the 21st century. Currently 8 million people die each year from smoking, 7 million are associated with active smoking, thus being the main risk factor for loss of disability-adjusted life years for men and the ninth most important risk factor for women. In previous studies it has been reported that approximately 21% (14%-30%) of subjects who have required hospitalization are active smokers, being higher in men than in women (28% vs 14%). The initiation of treatment for smoking cessation in this group of subjects has shown an effectiveness rate of up to 65% to maintain abstinence 6 to 12 months after discharge. The effectiveness has been analyzed in scenarios with only brief advice, in some others with the use of medications such as varenicline, bupropion and nicotine replacement therapy, however, the interventions have not been standardized for adequate analysis, which could contribute to the different results.",[189,274,27,275,276],"Tobacco Withdrawal","Nicotine Withdrawal","Nicotine Replacement Therapy",[166,278,279,280],"bupropion","nicotine replacement therapy","abstinence","2024-02-21",{"date":283,"type":34},"2024-02-23",{"date":285,"type":34},"2024-01-15",{"date":287,"type":21},"2026-06-15",{"name":289,"class":290},"National Institute of Respiratory Diseases, Mexico","OTHER_GOV"]